CMBC International: First coverage of We Livingstone Corporation-B (09887) with a "buy" rating. Target price is HKD 63.5.

Wisdom Financial APP learned that Zhongyin International released a research report stating that Visto Biotech-B (09887) focuses on developing immune therapies related to immune checkpoints, such as co-stimulatory agonists and checkpoint inhibitors, while expanding into other areas, such as CD3 T cell engagers and antibody-drug conjugates (ADC). The company has developed proprietary Leads Body and X-body platforms, which are engines for continuous drug discovery. The company is optimistic about Visto Biotech's development of PD-L1/4-1BB and TCE as the next generation of IO drugs, and has initiated coverage with a "buy" rating and a target price of HK$63.5.